全文获取类型
收费全文 | 70641篇 |
免费 | 4228篇 |
国内免费 | 1308篇 |
专业分类
耳鼻咽喉 | 104篇 |
儿科学 | 1846篇 |
妇产科学 | 794篇 |
基础医学 | 4957篇 |
口腔科学 | 517篇 |
临床医学 | 9394篇 |
内科学 | 22852篇 |
皮肤病学 | 173篇 |
神经病学 | 1242篇 |
特种医学 | 1648篇 |
外国民族医学 | 1篇 |
外科学 | 9008篇 |
综合类 | 10649篇 |
预防医学 | 2902篇 |
眼科学 | 94篇 |
药学 | 6062篇 |
81篇 | |
中国医学 | 3235篇 |
肿瘤学 | 618篇 |
出版年
2023年 | 992篇 |
2022年 | 1449篇 |
2021年 | 2356篇 |
2020年 | 2675篇 |
2019年 | 3265篇 |
2018年 | 2275篇 |
2017年 | 1990篇 |
2016年 | 1977篇 |
2015年 | 2215篇 |
2014年 | 4739篇 |
2013年 | 4983篇 |
2012年 | 3767篇 |
2011年 | 4503篇 |
2010年 | 3635篇 |
2009年 | 3667篇 |
2008年 | 3564篇 |
2007年 | 3526篇 |
2006年 | 3244篇 |
2005年 | 2939篇 |
2004年 | 2295篇 |
2003年 | 2019篇 |
2002年 | 1638篇 |
2001年 | 1564篇 |
2000年 | 1208篇 |
1999年 | 989篇 |
1998年 | 818篇 |
1997年 | 785篇 |
1996年 | 687篇 |
1995年 | 659篇 |
1994年 | 614篇 |
1993年 | 468篇 |
1992年 | 458篇 |
1991年 | 412篇 |
1990年 | 346篇 |
1989年 | 352篇 |
1988年 | 343篇 |
1987年 | 260篇 |
1986年 | 218篇 |
1985年 | 255篇 |
1984年 | 243篇 |
1983年 | 168篇 |
1982年 | 190篇 |
1981年 | 185篇 |
1980年 | 189篇 |
1979年 | 158篇 |
1978年 | 140篇 |
1977年 | 124篇 |
1976年 | 119篇 |
1975年 | 110篇 |
1973年 | 97篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
1.
Rolf Svedjeholm Gabriele Ferrari Farkas Vanky Örjan Friberg Jonas Holm 《Acta anaesthesiologica Scandinavica》2023,67(10):1373-1382
Background
Glutamate plays a key role for post-ischaemic recovery of myocardial metabolism. According to post hoc analyses of the two GLUTAMICS trials, patients without diabetes benefit from glutamate with less myocardial dysfunction after coronary artery bypass surgery (CABG). Copeptin reflects activation of the Arginine Vasopressin system and is a reliable marker of heart failure but available studies in cardiac surgery are limited. We investigated whether glutamate infusion is associated with reduced postoperative rises of plasma Copeptin (p-Copeptin) after CABG.Methods
A prespecified randomised double-blind substudy of GLUTAMICS II. Patients had left ventricular ejection fraction ≤0.30 or EuroSCORE II ≥3.0 and underwent CABG ± valve procedure. Intravenous infusion of 0.125 M L-glutamic acid or saline at 1.65 mL/kg/h was commenced 10–20 min before the release of the aortic cross-clamp and then continued for another 150 min P-Copeptin was measured preoperatively and postoperatively on day one (POD1) and day three. The primary endpoint was an increase in p-Copeptin from the preoperative level to POD1. Postoperative stroke ≤24 h and mortality ≤30 days were safety outcomes.Results
We included 181 patients of whom 48% had diabetes. The incidence of postoperative mortality ≤30 days (0% vs. 2.1%; p = .50) and stroke ≤24 h (0% vs. 3.2%; p = .25) did not differ between the glutamate group and controls. P-Copeptin increased postoperatively with the highest values recorded on POD1 without significant inter-group differences. Among patients without diabetes, p-Copeptin did not differ preoperatively but postoperative rise from preoperative level to POD1 was significantly reduced in the glutamate group (73 ± 66 vs. 115 ± 102 pmol/L; p = .02). P-Copeptin was significantly lower in the Glutamate group on POD1 (p = .02) and POD 3 (p = .02).Conclusions
Glutamate did not reduce rises of p-Copeptin significantly after moderate to high-risk CABG. However, glutamate was associated with reduced rises of p-Copeptin among patients without diabetes. These results agree with previous observations suggesting that glutamate mitigates myocardial dysfunction after CABG in patients without diabetes. Given the exploratory nature of these findings, they need to be confirmed in future studies. 相似文献2.
《Nefrología : publicación oficial de la Sociedad Espa?ola Nefrologia》2022,42(2):145-162
Renal sodium and water retention with resulting extracellular volume expansion and redistribution are hallmark features of heart failure syndromes. However, congestion assessment, monitoring, and treatment represent a real challenge in daily clinical practice. This document reviewed historical and contemporary evidence of available methods for determining volume status and discuss pharmacological aspects and pathophysiological principles that underlie diuretic use. 相似文献
3.
目的研究医联体背景下射血分数中间值的中老年急性失代偿心力衰竭(心衰)住院患者临床特征及1年内发生主要心血管事件的风险。方法回顾性队列研究, 连续收集天津市胸科医院心内科和天津河西医院诊区急性失代偿心衰住院患者180例, 根据入院后左心室射血分数(LVEF)将心衰患者分为射血分数低(HFrEF, LVEF< 40%)组70例(38.9%)、射血分数中间值(HFmEF, LVEF 40%~49%)组50例(27.8%)和射血分数保留(HFpEF, LVEF≥50%)组60例(33.3%), 比较3组患者临床特征及1年预后差异。结果 1年全因死亡和心血管死亡单因素Cox回归分析, HFrEF组与HFmEF组、HFpEF组与HFmEF组患者比较, 差异无统计学意义(均P>0.05);1年心衰再入院分析, HFrEF组47.1%(33例)较HFmEF组48.3%(29例)高、HFpEF组24.0%(12例)较HFmEF组高(HR分别为2.307、2.368, 95%CI:0.187~4.480、1.207~4.644, 均P<0.05);1年主要心血管事件HFrEF组57.1%... 相似文献
4.
《Revista portuguesa de cardiologia》2022,41(11):941-947
BackgroundThe MAGGIC risk score has been validated to predict mortality in patients with heart failure (HF).ObjectivesTo assess the score ability to predict hospitalization and death and to compare with natriuretic peptides.MethodsNinety-three consecutive patients (mean age 62±10 years) with chronic HF and left ventricular ejection fraction (EF) <50% were studied. The MAGGIC score was applied at baseline and the patients were followed for 219±86 days. MAGGIC score was compared with NT-proBNP in the prediction of events. The primary end point was the time to the first event, which was defined as cardiovascular death or hospitalization for HF.ResultsThere were 23 (24.7%) events (3 deaths and 20 hospitalizations). The median score in patients with and without events was, respectively, 20 [interquartile range 14.2–22] vs. 15.5 [11/21], p=0.16. A ROC curve was performed and a cutoff point of 12 points showed a sensitivity of 87% and specificity of 37% with an area under the curve of 0.59 (95% CI 0.48–0.69) which was lower than that of NT-proBNP (AUC 0.67; 95% CI 0.56–0.76). The mean event-free survival time for patients above and below this cutpoint was 248.8±13 vs. 290±13.7 days (log rank test with p=0.044). Using the COX proportional hazard model, age (p=0.004), NT-proBNP >1000 pg/mL (p=0.014) and the MAGGIC score (p=0.025) were independently associated with the primary outcome.ConclusionThe MAGGIC risk score was an independent predictor of events, including heart failure hospitalization. The addition of biomarkers improved the accuracy of the score. 相似文献
5.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(6):1361-1374
Background and aimsIn the absence of a gold standard or scientific consensus regarding the nutritional evaluation of heart failure (HF) patients, this study aimed to summarize and systematically evaluate the prognostic value of nutritional screening and assessment tools used for all-cause mortality in HF patients.Methods and resultsRelevant studies were retrieved from major databases (PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), WanFang Data, and China Biology Medicine disc (CMB)) and searched from the earliest available date until July 2021. If three or more studies used the same tool, meta-analysis using RevMan 5.3 was performed. This systematic review was registered at PROSPERO (number CRD42021275575). A total of 36 articles involving 25,141 HF patients were included for qualitative analysis and 31 studies for quantitative analysis. Meta-analysis of these studies indicated, poor nutritional status evaluated by using 5 nutritional screening tools (Prognostic Nutritional Index (PNI), Geriatric Nutritional Risk Index (GNRI), Controlling Nutritional Status Score (CONUT), Nutritional Risk Index (NRI), and Short Form Mini Nutritional Assessment (MNA-SF)) or 2 nutritional assessment tools (the Mini Nutritional Assessment (MNA) and Generated Subjective Global Assessment (SGA)) predicted all-cause mortality in HF patients. Of all tools analyzed, MNA had the maximum HR for mortality [HR = 2.62, 95%CI 1.11–6.20, P = 0.03] and MNA-SF [HR = 1.94, 95%CI 1.40–2.70, P<0.001] was the best nutritional screening tools.ConclusionPoor nutritional status predicted all-cause mortality in HF patients. MNA may be the best nutritional assessment tool, and MNA-SF is most recommended for HF patient nutritional screening. The application value of MNA, especially in patients with reduced left ventricular ejection fraction (LVEF), needs to be further confirmed. The clinical application value of Mini-Nutrition Assessment Special for Heart Failure (MNA-HF) and Global Leadership Initiative on Malnutrition (GLIM) in HF patients needs to be confirmed. 相似文献
6.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(8):1880-1885
Background and aimHeart failure (HF) and diabetes mellitus (DM) are burdensome chronic diseases with high lifetime risks and numerous studies indicate associations between HF and DM. The objective of this study was to investigate the direct and indirect costs of HF patients with and without DM.Methods and resultsPatients with a first-time diagnosis of HF from 1998 to 2016 were identified through nationwide Danish registries and stratified according to DM status into HF with or without DM. The economic healthcare cost analysis was based on both direct costs, including hospitalization, procedures, medication and indirect costs including social welfare and lost productivity. The economic burden was investigated prior to, at, and following diagnosis of HF. Patients with concomitant HF and DM were younger (median age 74 vs. 77), had more comorbidities and fewer were female as compared to patients with HF but without DM. The socioeconomic burden of concomitant HF and DM compared to HF alone was substantially higher; 45% in direct costs (€16,237 vs. €11,184), 35% in home care costs (€3123 vs. €2320), 8% in social transfer income (€17,257 vs. €15,994) and they had 27% lower income (€10,136 vs. €13,845). The economic burden peaked at year of diagnosis, but the difference became increasingly pronounced in the years following the HF diagnosis.ConclusionPatients with concomitant HF and DM had a significantly higher economic burden compared to patients with HF but without DM. 相似文献
7.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(8):1963-1971
Background and aimsThe relation of serum cystatin C with new-onset cardiovascular disease (CVD) remains uncertain. We aimed to evaluate the prospective associations of serum cystatin C and its change with new-onset CVD in Chinese general population.Methods and resultsA total of 7064 participants free of CVD at baseline were enrolled from the China Health and Retirement Longitudinal Study. The change in serum cystatin C was calculated as cystatin C concentration at 2015 wave minus that at baseline (2011 wave). The primary outcome was new-onset CVD, defined as self-reported physician-diagnosed heart disease, stroke, or both during follow-up. The secondary outcomes were new-onset heart disease, and new-onset stroke. During a median follow-up duration of 7.0 years, a total of 1116 (15.8%) subjects developed new-onset CVD. Overall, after the adjustments for eGFR and other important covariates, there was a positive association between serum cystatin C and new-onset CVD (per SD mg/L increment; adjusted HR, 1.13; 95%CI: 1.08,1.18). When cystatin C was assessed as quintiles, the adjusted HRs for participants in the second, third, fourth and fifth quintiles were 1.15 (95%CI: 0.93, 1.41), 1.37 (95%CI: 1.11, 1.68), 1.47 (95%CI: 1.19, 1.81), and 2.03 (95%CI: 1.60, 2.56), respectively, compared with those in quintile 1 (P for trend<0.001). Furthermore, there was a positive association between the increase in cystatin C concentration and the subsequent new-onset CVD (per SD mg/L increment; adjusted HR, 1.14; 95%CI: 1.02,1.27).ConclusionBoth serum cystatin C and its increase were positively associated with new-onset CVD among Chinese general population. 相似文献
8.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(9):2137-2146
Background and aimsLeptin is an adipocyte-derived peptide involved in energy homeostasis and body weight regulation. The position of leptin in cardiovascular pathophysiology remains controversial. Some studies suggest a detrimental effect of hyperleptinemia on the cardiovascular (CV) system, while others assume the role of leptin as a neutral or even protective factor. We have explored whether high leptin affects the mortality and morbidity risk in patients with stable coronary heart disease.Methods and resultsWe followed 975 patients ≥6 months after myocardial infarction or coronary revascularization in a prospective study. All-cause or cardiovascular death, non-fatal cardiovascular events (recurrent myocardial infarction, stroke, or any revascularization), and hospitalizations for heart failure (HF) we used as outcomes.High serum leptin concentrations (≥18.9 ng/mL, i.e., 4th quartile) were associated with worse survival, as well as with a higher incidence of fatal vascular events or hospitalizations for HF. Even after full adjustment for potential covariates, high leptin remained to be associated with a significantly increased 5-years risk of all-cause death [Hazard risk ratio (HRR) 2.10 (95%CIs:1.29–3.42), p < 0.003], CV death [HRR 2.65 (95%CIs:1.48–4.74), p < 0.001], and HF hospitalization [HRR 1.95 (95% CIs:1.11–3.44), p < 0.020]. In contrast, the incidence risk of non-fatal CV events was only marginally and non-significantly influenced [HRR 1.27 (95%CIs:0.76–2.13), p = 0.359].ConclusionsHigh leptin concentration entails an increased risk of mortality, apparently driven by fatal CV events and future worsening of HF, on top of conventional CV risk factors and the baseline status of left ventricular function. 相似文献
9.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(10):2338-2347
Background and aimsResting heart rate variability (HRV) and maximal fat oxidation (MFO) during exercise are both considered as a noninvasive biomarkers for early detection of cardiovascular risk factors. Thus, this study aimed to analyze the relationship between resting HRV parameters and MFO during exercise, and the intensity of exercise that elicit MFO (Fatmax) in healthy sedentary adults.Methods and resultsA total of 103 healthy young adults (22.2 ± 2.3 years old, 67% female; from the ACTIBATE cohort) and 67 healthy middle-aged adults (53.1 ± 5.0 years old, 52% female; from the FIT-AGEING cohort) were included in this cross-sectional study. HRV was assessed using a Polar RS800CX heart rate monitor, while MFO and Fatmax were determined during a graded exercise treadmill test using indirect calorimetry. No significant associations were observed for healthy young adults (standardized β coefficients ranged from ?0.063 to 0.094, and all P ≥ 0.347) and for middle-aged adults (standardized β coefficients ranged from ?0.234 to 0.090, and all P ≥ 0.056). Nevertheless, only a weak association was observed between one HRV parameter in time-domain (the percentage of R-R intervals that shows a difference higher than 50 ms [pNN50]) and MFO in the cohort of middle-aged adults (β coefficient = ?0.279, and P = 0.033).ConclusionThe results of this study suggest that resting HRV parameters are not associated with MFO and Fatmax during exercise in two independent cohorts of healthy sedentary young and middle-aged adults, respectively. 相似文献
10.